Literature DB >> 26979397

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Valerie M Jansen1, Ingrid A Mayer1, Carlos L Arteaga2.   

Abstract

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26979397      PMCID： PMC4891224          DOI： 10.1158/1078-0432.CCR-16-0100

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Molecular analysis for therapy choice: NCI MATCH.

Authors:  Barbara A Conley; James H Doroshow
Journal:  Semin Oncol       Date:  2014-05-22       Impact factor: 4.929

4.  A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Cynthia X Ma; Cesar Sanchez; Feng Gao; Robert Crowder; Michael Naughton; Timothy Pluard; Allison Creekmore; Zhanfang Guo; Jeremy Hoog; A Craig Lockhart; Austin Doyle; Charles Erlichman; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2016-01-18       Impact factor: 12.531

Review 5.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.

Authors:  Wen-I Wu; Walter C Voegtli; Hillary L Sturgis; Faith P Dizon; Guy P A Vigers; Barbara J Brandhuber
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

7.  Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.

Authors:  Chaitali Parikh; Vasantharajan Janakiraman; Wen-I Wu; Catherine K Foo; Noelyn M Kljavin; Subhra Chaudhuri; Eric Stawiski; Brian Lee; Jie Lin; Hong Li; Maria N Lorenzo; Wenlin Yuan; Joseph Guillory; Marlena Jackson; Jesus Rondon; Yvonne Franke; Krista K Bowman; Meredith Sagolla; Jeremy Stinson; Thomas D Wu; Jiansheng Wu; David Stokoe; Howard M Stern; Barbara J Brandhuber; Kui Lin; Nicholas J Skelton; Somasekar Seshagiri
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-07       Impact factor: 11.205

8.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Authors:  Sarat Chandarlapaty; Ayana Sawai; Maurizio Scaltriti; Vanessa Rodrik-Outmezguine; Olivera Grbovic-Huezo; Violeta Serra; Pradip K Majumder; Jose Baselga; Neal Rosen
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

9.  A kinase-independent function of AKT promotes cancer cell survival.

Authors:  Igor Vivanco; Zhi C Chen; Barbara Tanos; Barbara Oldrini; Wan-Ying Hsieh; Nicolas Yannuzzi; Carl Campos; Ingo K Mellinghoff
Journal:  Elife       Date:  2014-12-31       Impact factor: 8.140

10.  Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.

Authors:  Emily M Fox; María Gabriela Kuba; Todd W Miller; Barry R Davies; Carlos L Arteaga
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466
View more
  15 in total

1.  Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.

Authors:  Inchul You; Emily C Erickson; Katherine A Donovan; Nicholas A Eleuteri; Eric S Fischer; Nathanael S Gray; Alex Toker
Journal:  Cell Chem Biol       Date:  2019-12-16       Impact factor: 8.116

2.  Real-Time Analysis of AKT Signaling Activities at Single-Cell Resolution Using Cyclic Peptide-Based Probes.

Authors:  Fei Ji; Siwen Wang; Shiqun Shao; Priyanka Sarkar; Min Xue
Journal:  Methods Mol Biol       Date:  2022

3.  AKT constitutes a signal-promoted alternative exon-junction complex that regulates nonsense-mediated mRNA decay.

Authors:  Hana Cho; Elizabeth T Abshire; Maximilian W Popp; Christoph Pröschel; Joshua L Schwartz; Gene W Yeo; Lynne E Maquat
Journal:  Mol Cell       Date:  2022-06-07       Impact factor: 19.328

4.  The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.

Authors:  Piotr Kobialka; Helena Sabata; Sandra D Castillo; Mariona Graupera; Odena Vilalta; Leonor Gouveia; Ana Angulo-Urarte; Laia Muixí; Jasmina Zanoncello; Oscar Muñoz-Aznar; Nagore G Olaciregui; Lucia Fanlo; Anna Esteve-Codina; Cinzia Lavarino; Biola M Javierre; Veronica Celis; Carlota Rovira; Susana López-Fernández; Eulàlia Baselga; Jaume Mora
Journal:  EMBO Mol Med       Date:  2022-06-13       Impact factor: 14.260

5.  Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer.

Authors:  Omar Elakad; Björn Häupl; Vera Labitzky; Sha Yao; Stefan Küffer; Alexander von Hammerstein-Equord; Bernhard C Danner; Manfred Jücker; Henning Urlaub; Tobias Lange; Philipp Ströbel; Thomas Oellerich; Hanibal Bohnenberger
Journal:  NPJ Precis Oncol       Date:  2022-07-19

6.  A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Authors:  Cynthia X Ma; Vera Suman; Matthew P Goetz; Donald Northfelt; Mark E Burkard; Foluso Ademuyiwa; Michael Naughton; Julie Margenthaler; Rebecca Aft; Richard Gray; Amye Tevaarwerk; Lee Wilke; Tufia Haddad; Timothy Moynihan; Charles Loprinzi; Tina Hieken; Erica K Barnell; Zachary L Skidmore; Yan-Yang Feng; Kilannin Krysiak; Jeremy Hoog; Zhanfang Guo; Leslie Nehring; Kari B Wisinski; Elaine Mardis; Ian S Hagemann; Kiran Vij; Souzan Sanati; Hussam Al-Kateb; Obi L Griffith; Malachi Griffith; Laurence Doyle; Charles Erlichman; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2017-09-05       Impact factor: 13.801

7.  AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.

Authors:  Sizhi Paul Gao; Amber J Kiliti; Kai Zhang; Naresh Vasani; Ninghui Mao; Emmet Jordan; Hannah C Wise; Tripti Shrestha Bhattarai; Wenhuo Hu; Madeline Dorso; James A Rodrigues; Kwanghee Kim; Aphrothiti J Hanrahan; Pedram Razavi; Brett Carver; Sarat Chandarlapaty; Jorge S Reis-Filho; Barry S Taylor; David B Solit
Journal:  Mol Cancer Res       Date:  2020-12-10       Impact factor: 6.333

Review 8.  Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).

Authors:  Qi Wang; Xinyu Chen; Nissim Hay
Journal:  Br J Cancer       Date:  2017-05-30       Impact factor: 7.640

9.  AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.

Authors:  Marina Riggio; María C Perrone; María L Polo; María J Rodriguez; María May; Martín Abba; Claudia Lanari; Virginia Novaro
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

10.  The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.

Authors:  Hui Liu; Marcia N Paddock; Haibin Wang; Charles J Murphy; Renee C Geck; Adrija J Navarro; Gerburg M Wulf; Olivier Elemento; Volker Haucke; Lewis C Cantley; Alex Toker
Journal:  Cancer Discov       Date:  2020-06-08       Impact factor: 38.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.